Resisting Zika

Undeterred, researchers are tackling a global crisis from multiple directions

Jennifer Govero, a senior scientist and lab manager, and virologist Michael S. Diamond, MD, PhD, analyze a plaque assay of the Zika virus. (Photo: Robert Boston/Washington University School of Medicine)

Throughout 2015, increasingly worrisome reports trickled out of Brazil about an obscure virus called Zika. A member of the flavivirus family, which includes dengue and West Nile, Zika was a new arrival in the Americas. Identified almost 70 years earlier in Africa, the virus was thought to cause only mild disease. In Brazil, however, it became associated with birth defects and a progressive form of paralysis known as Guillain-Barré syndrome.

As the Zika epidemic took hold, leaders at the National Institutes of Health (NIH) realized they needed to learn about the virus quickly. They started phoning select scientists, and offered funding for Zika research.

One of those researchers, Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Internal Medicine and Infectious Diseases, is known for his studies on flaviviruses. When the NIH called, the virologist already had been working on Zika for six months, collaborating with experts across the School of Medicine — in neurobiology, reproductive biology, structural biology, immunology and other fields — to determine what damage the virus could do and what could be done to stop it.

Less than a year later, the School of Medicine is one of the hotspots of Zika research.

Read the full story in the School of Medicine’s Outlook Magazine.

Leave a Comment

Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.